Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: OpenUrlCrossRefPubMed
There is a biological and epidemiological evidence to suggest that high oestrogen levels retard the progression of atherogenesis, reducing the risk of myocardial infarction. Whether such an effect is evident following a first myocardial infarction is unclear. A randomised controlled trial was carried out to investigate. Following completion of the trial the authors continued the follow-up in order to evaluate the long-term safety of unopposed oestrogen.
Women aged 50–79 years who sustained a first myocardial infarction (MI) and who had not used hormone replacement therapy in the preceding year were randomised …
Competing interests SS has in the past consulted, and presently consults with, Bayer Schering and with other manufacturers of female hormones.
Provenance and peer review Not commissioned; internally peer reviewed.